Starbucks is stopping coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy due to high costs, following a trend among large employers. This could limit …

Written by Prosper Junior Bakiny for The Motley Fool -> Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. T…

Sia and Mikael Lilja decided to start over in Japan after realizing children were no longer part of their future.

Researchers have identified a specific mushroom that triggers Lilliputian hallucinations, where individuals see tiny human figures after consumption. This disc…

Lebanese and international rights groups have accused Israel of intentionally targeting and killing a Lebanese journalist and obstructing medical workers from …

Human rights organizations have called an Israeli airstrike in southern Lebanon, which killed journalist Amal Khalil and injured Zeinab Faraj, a potential war …

Three people face felony charges after a loose dog killed a toddler in Arkansas. The tragedy highlights the state’s high rate of dog attacks and spurs calls fo…

Three rights groups have released findings of a probe into the Israeli attack which killed Lebanese journalist Amal Khalil in April. The investigation by Human…

Written by Joe Tenebruso for The Motley Fool -> Shares of Eli Lilly (NYSE: LLY) rose on Monday after the U.S. Food and Drug Administration (FDA) approved the …

Eli Lilly (LLY) stock extended gains on Wednesday after the pharmaceutical behemoth announced a new direct-to-consumer (DTC) collaboration with CVS Health (CVS…

The strength of its GLP-1 business suggests the stock still has more room to run.